07:00 , Apr 15, 2013 |  BC Week In Review  |  Clinical News

DMUC5754A: Phase I data

An open-label, dose-escalation, U.S. Phase I trial in 44 evaluable patients with advanced recurrent platinum-resistant ovarian cancer showed that 0.3-3.2 mg/kg IV DMUC5754A every 3 weeks led to 1 complete response and 4 partial responses,...